Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Overweight rating on Pharvaris (NASDAQ:PHVS) and increased the price target from $32 to $35.
December 07, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst reaffirms Overweight rating on Pharvaris and raises price target to $35, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Matthew Harrison suggests a strong conviction in Pharvaris's potential, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100